Drugs facing NCE-1 in 2023

1. List of Accrufer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802973 SHIELD TX Crystalline forms of ferric maltol
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(8 years from now)

US10179120 SHIELD TX Dosage regimen of ferric trimaltol
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Aklief drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Oct, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(2 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(10 years from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

3. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(8 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(13 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(13 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(15 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

4. List of Balversa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(8 years from now)

US9902714 JANSSEN BIOTECH Quinoxaline derivatives useful as FGFR kinase modulators
Mar, 2035

(12 years from now)

US10898482 JANSSEN BIOTECH Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Feb, 2036

(13 years from now)

US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Brukinsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen

Dosage: CAPSULE;ORAL

More Information on Dosage

6. List of Caplyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Feb, 2029

(6 years from now)

US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(6 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(5 years from now)

US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Mar, 2029

(6 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(6 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
May, 2029

(6 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(6 years from now)

USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders
Dec, 2029

(6 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(11 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(11 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(11 years from now)

US11052084 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 20 December, 2019

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways

Dosage: CAPSULE;ORAL

More Information on Dosage

7. List of Dalvance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115564 ALLERGAN Stable pharmaceutical compositions of dalbavancin and methods of administration
Nov, 2023

(9 months from now)

US8143212 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US7119061 ALLERGAN Dalbavancin compositions for treatment of bacterial infections
Nov, 2023

(9 months from now)

US6900175 ALLERGAN Methods of administering dalbavancin for treatment of bacterial infections
Dec, 2023

(10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2019
New Patient Population (NPP) Jul 22, 2024
Generating Antibiotic Incentives Now (GAIN) May 23, 2024

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

8. List of Exem Foam Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(7 years from now)

US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(12 years from now)

US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

9. List of Givlaari drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(1 year, 24 days ago)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(10 months from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 1 month from now)

US11530408 ALNYLAM PHARMS INC Therapeutic compositions
May, 2024

(1 year, 3 months from now)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(6 years from now)

US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
May, 2033

(10 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

10. List of Ibsrela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(6 years from now)

US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Dec, 2029

(6 years from now)

US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage

11. List of Inrebic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7825246 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(3 years from now)

US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases
Jun, 2028

(5 years from now)

US10391094 IMPACT Compositions and methods for treating myelofibrosis
Jun, 2032

(9 years from now)

US11400092 IMPACT Methods of treating myeloproliferative disorders
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent

Dosage: CAPSULE;ORAL

More Information on Dosage

12. List of Kimyrsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

13. List of Mayzent drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 26, 2024
M Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

NCE-1 date: March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage

14. List of Nourianz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727994 KYOWA KIRIN Methods of treating patients suffering from movement disorders
Jan, 2023

(15 days ago)

US7727993 KYOWA KIRIN Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
Jan, 2023

(5 days ago)

US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 27 August, 2019

Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives said l-dopa therapy

Dosage: TABLET;ORAL

More Information on Dosage

15. List of Nubeqa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

16. List of Orbactiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

17. List of Oxbryta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(10 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(9 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(10 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(12 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(13 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; Increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

18. List of Piqray drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

19. List of Rinvoq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(7 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(7 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(13 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11365198 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US10202393 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

US11512092 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

20. List of Rozlytrek drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9029356 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8299057 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Mar, 2029

(6 years from now)

US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085558 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9255087 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9616059 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US8673893 GENENTECH INC Substituted indazole derivatives active as kinase inhibitors
Jul, 2028

(5 years from now)

US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

US10231965 GENENTECH INC Molecules for administration to ROS1 mutant cancer cells
Feb, 2035

(12 years from now)

US10561651 GENENTECH INC Methods for treating neuroblastoma
Feb, 2035

(12 years from now)

US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2026
New Chemical Entity Exclusivity (NCE) Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage

21. List of Scenesse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(2 years from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 8, 2026
New Chemical Entity Exclusivity (NCE) Oct 8, 2024

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage

22. List of Sivextro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
New Patient Population (NPP) Jun 19, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

23. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877806 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US9604917 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US10351517 JAZZ Treatment of sleep-wake disorders
Jun, 2026

(3 years from now)

US8440715 JAZZ Treatment of sleep-wake disorders
Aug, 2027

(4 years from now)

US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US10959976 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10912754 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

24. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

25. List of Trikafta (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(4 years from now)

US11426407 VERTEX PHARMS INC NA
Oct, 2035

(12 years from now)

US10758534 VERTEX PHARMS INC NA
Oct, 2035

(12 years from now)

US11453655 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(3 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Aug, 2027

(4 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Nov, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof
Aug, 2029

(6 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
Mar, 2031

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
Jul, 2033

(10 years from now)

US11517564 VERTEX PHARMS INC Methods of treatment for cystic fibrosis
Dec, 2037

(14 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 8, 2024
New Chemical Entity Exclusivity (NCE) Oct 21, 2024
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 21 October, 2019

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; Treatment of cystic fibrosis in patients aged 12 years and older who have one f508del mutation and one r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene using a solid composition comprising elexacaftor, tezacaftor, amorphous ivacaftor, and less than about 30% crystalline ivacaftor; Treatment of cf in patients 12 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva; Treatment of cf in patients 6 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition according to claim 1 of us 10081621; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; And another composition comprising ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily elx (200 mg or 100 mg); Tez; And iva; Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva; Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a compound of claim 1 or composition of claim 29 of us11426407

Dosage: TABLET;ORAL

More Information on Dosage

26. List of Turalio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(10 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity
Apr, 2028

(5 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(10 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 2, 2024
Orphan Drug Exclusivity (ODE) Aug 2, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage

27. List of Ubrelvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8912210 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US10117836 ALLERGAN Tablet formulation for CGRP active compounds
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Vijoice drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476268 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2029

(6 years from now)

US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

CN102149711B NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

CN102149711A NOVARTIS Organic Compounds
Sep, 2029

(6 years from now)

IN307469B NOVARTIS The Compound (S)-Pyrrolidine-1,2-Dicarboxylic Acid 2-Amide-1- ({4-Methyl-5-[2-(2,2,2-Trifluoro-1,1-Dimethyl-Ethyl)- Pyridin-4-Yl]-Thiazol-2-Yl}-Amide)
Sep, 2029

(6 years from now)

EP2331537A1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

EP2331537B1 NOVARTIS 1-((5-Heteroarylthiazol-2-Yl)Aminocarbonyl)Pyrrolidine-2-Carboxamide Derivatives As Phosphatidylinositol 3-Kinase (Pi3K) Inhibitors Useful In The Treatment Of Proliferative Diseases
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 24, 2024

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 05 April, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

29. List of Vyleesi (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6794489 PALATIN TECHNOLOGIES Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286034 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

US9700592 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

US9352013 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

30. List of Vyndamax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(1 year, 2 months from now)

US9770441 FOLDRX PHARMS Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2023

(10 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage

31. List of Vyndaqel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(10 months from now)

US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2023

(10 months from now)

US8653119 FOLDRX PHARMS Methods for treating transthyretin amyloid diseases
Jan, 2024

(11 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: May, 2023

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage

32. List of Vyondys 53 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

USRE47691 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 12, 2026
New Chemical Entity Exclusivity (NCE) Dec 12, 2024

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

33. List of Wakix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8207197 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Mar, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354430 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Feb, 2026

(3 years from now)

US8486947 HARMONY Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
Sep, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 14, 2024
Orphan Drug Exclusivity (ODE) Oct 13, 2027
New Indication (I) Oct 13, 2023

Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 14 August, 2019

Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating cataplexy in patients with narcolepsy

Dosage: TABLET;ORAL

More Information on Dosage

34. List of Xpovio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9714226 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US8999996 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Sep, 2032

(9 years from now)

US10519139 KARYOPHARM THERAPS Polymorphs of Selinexor
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079865 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US10544108 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

US11034660 KARYOPHARM THERAPS Hydrazide containing nuclear transport modulators and uses thereof
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2027
New Chemical Entity Exclusivity (NCE) Jul 3, 2024
New Indication (I) Jun 22, 2023

Drugs and Companies using SELINEXOR ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 03 July, 2019

Treatment: Xpovio is indicated in combination with dexamethasone to treat relapsed or refractory multiple myeloma (refractory to at least an anti-cd38 mab, 2 proteasome inhibitors and 2 immunomodulatory agents) in adults who received at least 4 prior therapies; Xpovio is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl), not otherwise specified, including dlbcl arising from follicular lymphoma, after at least 2 lines of systemic therapy; Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Dosage: TABLET;ORAL

More Information on Dosage

35. List of Zerbaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(5 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US11278622 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2019
New Patient Population (NPP) Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN) Dec 19, 2024

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Methods of treating bacterial illnesses; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

36. List of Zulresso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US7635773 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9750822 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10117951 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10322139 SAGE THERAP Neuroactive steroid formulations and methods of treating CNS disorders
Jan, 2033

(9 years from now)

US10251894 SAGE THERAP Anticonvulsant activity of steroids
Nov, 2033

(10 years from now)

US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof
Mar, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
New Patient Population (NPP) Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in